following a full submission:
ixekizumab (Taltz®) is accepted for restricted use within NHSScotland.
Indication under review: ixekizumab, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.
SMC restriction: patients whose disease has not responded adequately to at least two conventional DMARDs given either alone or in combination, and who have had an inadequate response to a tumour necrosis factor (TNF)-inhibitor.
Two phase III studies demonstrated superiority of ixekizumab when compared with placebo in reducing signs and symptoms of psoriatic arthritis in patients who had not previously received a biologic medication and those with an inadequate response or intolerance to TNF-inhibitors.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ixekizumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
- Medicine name:
- ixekizumab (Taltz)
- SMC ID:
- Treatment alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug therapies.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Date advice published:
- 08 October 2018